首页> 美国卫生研究院文献>Journal of Personalized Medicine >Treatment-Resistant Depression Revisited: A Glimmer of Hope
【2h】

Treatment-Resistant Depression Revisited: A Glimmer of Hope

机译:重新审视治疗抑郁症:一个充满希望的辉光

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Major Depressive Disorder (MDD) is a highly prevalent psychiatric disorder worldwide. It causes individual suffering, loss of productivity, increased health care costs and high suicide risk. Current pharmacologic interventions fail to produce at least partial response to approximately one third of these patients, and remission is obtained in approximately 30% of patients. This is known as Treatment-Resistant Depression (TRD). The burden of TRD exponentially increases the longer it persists, with a higher risk of impaired functional and social functioning, vast losses in quality of life and significant risk of somatic morbidity and suicidality. Different approaches have been suggested and utilized, but the results have not been encouraging. In this review article, we present new approaches to identify and correct potential causes of TRD, thereby reducing its prevalence and with it the overall burden of this disease entity. We will address potential contributory factors to TRD, most of which can be investigated in many laboratories as routine tests. We discuss endocrinological aberrations, notably, hypothalamic-pituitary-adrenal (HPA) axis dysregulation and thyroid and gonadal dysfunction. We address the role of Vitamin D in contributing to depression. Pharmacogenomic testing is being increasingly used to determine Single Nucleotide Polymorphisms in Cytochrome P450, Serotonin Transporter, COMT, folic acid conversion (MTHFR). As the role of immune system dysregulation is being recognized as potentially a major contributory factor to TRD, the measurement of C-reactive protein (CRP) and select immune biomarkers, where testing is available, can guide combination treatments with anti-inflammatory agents (e.g., selective COX-2 inhibitors) reversing treatment resistance. We focus on established and emerging test procedures, potential biomarkers and non-biologic assessments and interventions to apply personalized medicine to effectively manage treatment resistance in general and TRD specifically.
机译:主要抑郁症(MDD)是全球普遍普遍的精神疾病。它会导致个体痛苦,生产力损失,增加医疗保健成本和高自杀风险。目前的药理学干预措施未能为这些患者的大约三分之一产生至少部分反应,并且在大约30%的患者中获得缓解。这称为耐治疗抑郁(TRD)。 TRD的负担呈指数级增长的持续增长越长,功能性和社会功能受损的风险较高,生活质量造成巨大损失以及严峻风格和自由性的重要风险。已经提出和利用了不同的方法,但结果并未令人鼓舞。在本综述文章中,我们提出了识别和纠正TRD的潜在原因的新方法,从而降低了普遍存在和这种疾病实体的整体负担。我们将解决TRD的潜在缴费因素,大部分可以在许多实验室中调查作为常规测试。我们讨论内分泌畸变,特别是下丘脑 - 垂体 - 肾上腺(HPA)轴缺陷和甲状腺和甲状腺功能障碍。我们解决了维生素D在抑郁症方面的作用。药物替代试验越来越多地用于确定细胞色素P450,血清素转运蛋白,COMT,叶酸转化(MTHFR)中的单核苷酸多态性。由于免疫系统的作用被认为是潜在的Trd的主要贡献因素,C反应蛋白(CRP)的测量和选择可用的免疫生物标志物,可以指导具有抗炎剂的组合治疗(例如,选择性COX-2抑制剂)反转治疗抗性。我们专注于建立和新兴的测试程序,潜在的生物标志物和非生物学评估和干预措施,以应用个性化药物,以有效地管理一般和TRD的治疗阻力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号